Objective: 30 cases of non-obese patients with type 2 diabetes, 30 cases of obese patients with type 2 diabetes and 30 cases of healthy controls were selected to detect the levels of serum resistin, TNF-α, FFA, fasting blood glucose, fasting insulin, total cholesterol and triglycerides.
INTRODUCTION
With the improvement of living standards, diet structure and social aging problem of human beings, the incidence of type 2 diabetes increases every year, and has become a global epidemic. Type 2 diabetes can cause multiple organ damage, the incidence of complications and the mortality serious threat people's health and reduce the people's quality of life.
However, the pathogenesis of type 2 diabetes is not very clear yet, therefore, investigating the pathogenesis of type 2 diabetes is a common research for today's diabetes scholars. Recently, American researcher Steppan et al (1) identified a new hormone secreted by fat cells, that is resistin, which plays the role of producing insulin resistance, elevating blood glucose levels, and causing obesity by adipose cell proliferation and reproduction, the synthesis and secretion are affected by regulation of insulin, TNF-α, fatty acids and other cytokines.
Resistin may well explain the relationship among insulin resistance, obesity and diabetes, which is a breakthrough in diabetes and obesity research. Meanwhile, the contact between TNF-α and FFA with diabetes and insulin resistance has attracted everyone's attention, and epidemiological and experimental studies have pointed out the TNF-α, FFA's role in insulin resistance. Early prevention and treatment from the point of insulin resistance often prevent or delay the development of type 2 diabetes in a certain extent. Up to now, few studies abroad are about the changes and significance resistin, TNF-α and FFA in insulin resistance, as well as the interactions, but no reports at home.
In this study, the serum concentration changes of resistin, TNF-α, FFA and the interactions with fasting glucose and insulin were individually observed to discuss the main factors affected serum resistin, TNF-α, FFA and the relationship among them and their correlation with insulin resistance.
MATERIALS AND METHODS
All the 90 cases were selected from inpatients and healthy outpatients in our hospital, including 45 males and 45 females, with mean age of (52±13) years old, all subjects had no autoimmune diseases, cancer and chronic infectious diseases, and the tested patients had no acute infectious diseases and ketoacidosis on the day and in nearly two weeks. Three groups was divided according to glucose (the new DM WHO diagnostic criteria in 1998) and BMI (adult obesity standard in Asia-Pacific region from WHO): non-obese type 2 diabetes (Nonobese DM) group, obese type 2 diabetes (Obese DM) group and normal control group. This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Linyi city People's Hospital. Written informed consent was obtained from all participants.
All objects needed to be fasted for 10 hours, and the height, weight, waist and hip circumference were measured by special staff. 5 ml elbow vein morning blood was extracted, All data were inputted into the computer, and analyzed using SPSS10.0 statistical software. The statistical results were expressed as x ± s, the data were tested by normality test or homogeneity of variance test, then the difference among the groups was performed by t test, and correlation coefficients was used to evaluate the correlation among variables, stepwise multiple regression analysis was used to perform multivariate analysis.
RESULTS
The serum resistin, TNF-α and FFA in the normal control group, non-obese diabetic group and obese diabetic group increased in turn, and they were the lowest in the normal control group, followed by non-obese diabetic group, and the highest average was that of the obese diabetic group, there were significant differences between each two groups (P < 0.05, Table   1 ).
Seen from Taking Homa-IR as the dependent variable, and age, BMI, TG, TC, serum resistin and TNF-α, FFA levels as independent variables to perform multiple regression analysis, it was found that Homa-IR was significant correlation with resistin, TNF-α and FFA.
DISCUSSION
Adipose tissues were not only the body's energy storage organ, but also an important endocrine organ. In recent years, the effects of resistin, tumor necrosis factor and free fatty acids secreted by adipose on insulin aroused widespread concern in clinical, several studies showed that these factors were involved in the process of insulin sensitivity damage (2).
Resistin was a new peptide signaling molecules found by Steppan in 2001 (1), and the plasma concentrations of the polypeptide was apparent suppressed by the insulin-sensitizing thiazolidinediones (TZDs), it was considered now that resistin is an intermediate medium between obesity and diabetes. Insulin resistance was a common phenomenon in patients with diabetes; the excessive secreted insulin caused hyperinsulinemia due to the body's decreasing utilization of insulin. Many methods were available to evaluate insulin resistance, and the most common one was calculating Homa IR (IRI) through fasting plasma glucose and fasting insulin levels (3).
In this study, the resistin levels of the normal control group, non-obese diabetic group and obese diabetic group gradually increased, and positively correlated with BMI, FPG, The possible mechanism may be the binding ability of resistin to insulin receptors on sensitive tissues, then acted to one or several loci of insulin (6) and played the role of antiinsulin-stimulated uptake of glucose. The body would produce insulin resistance when the resistin concentration was too high, then lead to increased blood sugar, suggesting that resistin may impair or inhibit β cell insulin secretion. Further comparison of resistin mRNA levels in different parts of adipose tissues found that the resistin mRNA levels of human abdominal fat pad was 4.18 times higher than that of thigh, which was likely to explain increased risk of the centrally obese type 2 diabetes (7). But there were also reports considered that resistin levels was independent of insulin resistance (8, 9) .
TNF-α was a cytokine secreted by activated monocytes, macrophages and adipocytes (10) , which involved in the immune protection and immune injury with a dual biological role, and recent researches studied its closely association with insulin resistance (11) . The study found that TNF-α level of patients with diabetes was higher than that of the normal control group, and the concentrations of TNF-α in obese diabetic patients was the highest. Study also found that the TNF-α level of patients with presence of insulin resistance in type 2 diabetes patients was higher than those without insulin resistin (12) Recent studies also found that the TNF-α converting enzyme levels in the abdominal fat tissue of the visceral obesity patients was elevated to lead to increased activity of TNF-α and increased insulin resistance, thereby promoted fat synthesis and obesity. In addition, TNF-α was also involved in a number of chronic diabetic complications, such as diabetic nephropathy, retinopathy, atherosclerosis and peripheral neuropathy (16, 17) . And this study also found that FFA concentration in diabetic patients was significantly higher than that in non-obese and obese groups. Meanwhile, FFA and blood glucose were also correlated with IRI, suggesting that FFA was also an important factor caused insulin resistance.
TNF-α could not only inhibit gene expression and generation of resistin, but also play a synergistic biological effect for resistin to play the role of insulin resistance. Meanwhile, TNF-α had interaction with resistin. TNF-α was involved in insulin resistance, but TNF-α was a negative regulator of resistin, which could inhibit resistin mRNA expression, suggesting that TNF-α was negative regulatory factor of resistin expression (18, 19) , the process may be associated with PKA and mitogen-activated protein kinase (MAPR) dependent pathway, and other factors led to the elevated resistin levels could not be ruled out (20) .
Therefore, in the prevention and treatment of type 2 diabetes, in addition to actively control blood sugar levels, weight losing and active lipid-lowering therapy should be also considered, and thus reduces insulin resistance. Both lose weight or taking insulin sensitizers (thiazolidinediones, TZDs) can stimulate drop of TNF-α levels, correct hyperinsulinemia and reduce insulin resistance (21) , and the above effect could also be achieved by using TNF-α inhibitors or TNF-α antibody with the same principle, which has been confirmed by animal experiments (15, 22) . Similarly, lowering the resistin levels, counteract the biological activity of resistinin or giving resistin receptor antagonist were the future study direction of drug development.
In summary, more resistin, TNF-α and FFA secreted by adipose tissue of the obese diabetic patients would result in more severe insulin resistance, and the elevated blood sugar levels were also covered by high levels of insulin, so the diabetic patients treated by reducing glucose must pay attention to weight loss at the same time. It should not only prevent high blood sugar but also the occurrence of hyperinsulinemia. Starting from this perspective, the drugs for reducing insulin resistance, such as resistin inhibitors and TNF-α antibody, were developed to reduce insulin resistance, improve hypoglycemic drug efficacy, and finally achieve the purpose of well controlling diabetes.
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